Good Chance AstraZeneca (AZN) Releases MYSTIC Top-Line Results Tomorrow - BMO

BMO analyst Alex Arfaei thinks there is a good chance AstraZeneca (NYSE: AZN) will release the MYSTIC top-line results tomorrow.

"We continue to believe that there is a reasonable probability that MYSTIC shows positive PFS (combo vs. chemo)," he commented. "However, the uncertainty associated with IO trials has increased, and MYSTIC has plenty of it. We doubt that the PD-1+CTLA4 combos will show meaningfully differentiated clinical profile, and expected a fragmented market."

You May Also Be Interested In

• Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso
• Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
• JPMorgan Upgrades Bajaj Housing Finance (BAJAJHFL:IN) to Neutral